Adjuvant therapy

February 6, 2019

Knight Therapeutics Acquires Exclusive Marketing Rights to Nerlynx in Canada

News

Breast cancer treatment Nerlynx (neratinib) will be exclusively commercialized in Canada by Knight Therapeutics, under an agreement with the therapy’s developer, Puma Biotechnology. Nerlynx is currently being reviewed by Health Canada as a ... Read more

September 7, 2018

Health Canada Approves Perjeta Combo Therapy for Early Breast Cancer After Surgery

News

Health Canada has approved the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy to prevent the recurrence of early breast cancer after surgery. The combination is meant ... Read more

June 1, 2017June 1, 2017

Keytruda Shows Meaningful Clinical Benefit When Combined with Standard Therapy for Aggressive Breast Cancer

News

Two independent studies have added new evidence to the benefits of combined therapies with Merck‘s PD-1 inhibitor Keytruda (pembrolizumab) for the treatment of aggressive triple-negative breast cancer (TNBC). Adding Keytruda to standard therapies ... Read more